

# Takeda

Takeda is focused on creating better health for people and a brighter future for the world. We aim to discover and deliver life-transforming treatments in our core therapeutic and business areas, including gastrointestinal and inflammation, rare diseases, plasma-derived therapies, oncology, neuroscience and vaccines. Together with our partners, we aim to improve the patient experience and advance a new frontier of treatment options through our dynamic and diverse pipeline. As a leading values-based, R&D-driven biopharmaceutical company headquartered in Japan, we are guided by our commitment to patients, our people and the planet. Our employees in approximately 80 countries and regions are driven by our purpose and are grounded in the values that have defined us for more than two centuries.

## Values: Takeda-ism

We are guided by our values of Takeda-ism, which incorporate Integrity, Fairness, Honesty and Perseverance, with Integrity at the core. They are brought to life through actions based on Patient-Trust-Reputation-Business, in that order.



### Brought to life through actions based on:

1. Putting the patient first.
2. Building trust with society.
3. Reinforcing our reputation.
4. Developing a sustainable business.

## Areas of Focus

We focus on innovations that contribute to making a difference in people's lives. We aim to discover and deliver life-transforming treatments in our core therapeutic and business areas, including gastrointestinal and inflammation, rare diseases, plasma-derived therapies, oncology, neuroscience and vaccines.



## Takeda Singapore

Takeda has maintained a presence in Asia-Pacific for more than 50 years and entered Singapore in 2008. In 2015, Takeda established its regional headquarters in Singapore to harness the connectivity to markets in the regional to expand its network. Operations in the region include 1,700 staff in 10 countries.

Takeda Manufacturing Singapore Site was officially opened in 2014 and is Takeda's only biologics manufacturing facility in Asia. The site has around 400 employees and produces three recombinant clotting factors to treat rare blood disorders for the global market.



### REGIONAL HQ FOR GROWTH & EMERGING MARKETS BUSINESS UNIT

Regional headquarters for Takeda's Growth & Emerging Markets Business Unit (GEM), India & Southeast Asia (I-SEA) and Taiwan, Australia & South Korea (TAS) multi-country organization offices, Singapore local commercial operations and hub location for global functions

**225**  
EMPLOYEES



**BY GENDER**  
62% FEMALE • 38% MALE



**36**  
NATIONALITIES



**AGE**  
64% >40 YEARS OLD



### SINGAPORE MANUFACTURING SITE

Biotechnology manufacturing site specialised in recombinant technology for hematology therapies

**400**  
EMPLOYEES



**BY GENDER**  
40% FEMALE • 60% MALE



**9**  
NATIONALITIES



**AGE**  
57% <40 YEARS OLD



**PRODUCTION**  
24/7 • 365



**SUPPLY**  
18 GLOBAL  
MARKETS WORLDWIDE  
(SUCH AS EU, USA, JAPAN)



**EDUCATIONAL LEVEL**  
70% HAS MINIMUM UNIVERSITY DEGREE



**PRODUCTS**

Three recombinant products to treat: Hemophilia A (Factor VIII), Hemophilia B (Factor IX), congenital thrombotic thrombocytopenic purpura (cTTP)



### SUSTAINABILITY



**1st** Platinum Positive Energy Building in Takeda network and first of its kind within the biopharmaceutical industry in Singapore, certified by Singapore's Building Construction Authority Green Mark scheme - powered by 1600 sqm of solar energy

Quality laboratory received highest certification for laboratory sustainability practices by *My Green Lab*, a non-profit organization. The certification is considered gold standard around the world, recognized by United Nations Race to Zero campaign as a key measure of progress towards a zero-carbon future.